The role of tumor-infiltrating lymphocytes in papillary thyroid carcinomas

2011 ◽  
Vol 34 (9) ◽  
pp. 733-733 ◽  
Author(s):  
L. L. Cunha ◽  
F. A. Soares ◽  
J. Vassallo ◽  
L. S. Ward
Keyword(s):  
Tumor Infiltrating Lymphocytes ◽  
Papillary Thyroid ◽  
Thyroid Carcinomas ◽  
Infiltrating Lymphocytes

scholarly journals Prognostic Role of Tumor‐Infiltrating Lymphocytes and Tumor Budding in Early Oral Tongue Carcinoma

2021 ◽  
Author(s):  
Yukiko Hori ◽  
Akira Kubota ◽  
Tomoyuki Yokose ◽  
Madoka Furukawa ◽  
Takeshi Matsushita ◽  
...  
Keyword(s):  
Tumor Infiltrating Lymphocytes ◽  
Tumor Budding ◽  
Tongue Carcinoma ◽  
Oral Tongue ◽  
Prognostic Role ◽  
Infiltrating Lymphocytes

scholarly journals Immunity and cancer: role of tumor-infiltrating lymphocytes in triple-negative breast cancer

2021 ◽  
Vol 49 (1) ◽  
pp. 20-28
Author(s):  
Ana Tečić-Vuger ◽  
◽  
Robert Šeparović ◽  
Ljubica Vazdar ◽  
Mirjana Pavlović ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

scholarly journals The Immune Response to Tumors as a Tool toward Immunotherapy

2011 ◽  
Vol 2011 ◽  
pp. 1-12 ◽  
Author(s):  
F. Pandolfi ◽  
R. Cianci ◽  
D. Pagliari ◽  
F. Casciano ◽  
C. Bagalà ◽  
...  
Keyword(s):  
Immune Response ◽  
Monoclonal Antibodies ◽  
Cancer Colorectal ◽  
Immune Cell ◽  
Cytotoxic T Cells ◽  
Tumor Infiltrating Lymphocytes ◽  
Hematologic Malignancies ◽  
The Novel ◽  
Infiltrating Lymphocytes

Until recently cancer medical therapy was limited to chemotherapy that could not differentiate cancer cells from normal cells. More recently with the remarkable mushroom of immunology, newer tools became available, resulting in the novel possibility to attack cancer with the specificity of the immune system. Herein we will review some of the recent achievement of immunotherapy in such aggressive cancers as melanoma, prostatic cancer, colorectal carcinoma, and hematologic malignancies. Immunotherapy of tumors has developed several techniques: immune cell transfer, vaccines, immunobiological molecules such as monoclonal antibodies that improve the immune responses to tumors. This can be achieved by blocking pathways limiting the immune response, such as CTLA-4 or Tregs. Immunotherapy may also use cytokines especially proinflammatory cytokines to enhance the activity of cytotoxic T cells (CTLs) derived from tumor infiltrating lymphocytes (TILs). The role of newly discovered cytokines remains to be investigated. Alternatively, an other mechanism consists in enhancing the expression of TAAs on tumor cells. Finally, monoclonal antibodies may be used to target oncogenes.

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

2019 ◽  
Vol 343 ◽  
pp. 103753 ◽  
Author(s):  
Giuseppe Badalamenti ◽  
Daniele Fanale ◽  
Lorena Incorvaia ◽  
Nadia Barraco ◽  
Angela Listì ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

scholarly journals PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Bruna Cerbelli ◽  
Angelina Pernazza ◽  
Andrea Botticelli ◽  
Lucio Fortunato ◽  
Massimo Monti ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Triple Negative ◽  
Univariate Analysis ◽  
Tumor Infiltrating Lymphocytes ◽  
Predictive Biomarker ◽  
Complete Response ◽  
Response To Therapy ◽  
Neoplastic Progression ◽  
Infiltrating Lymphocytes

Triple negative breast cancer (TNBC) has an aggressive clinical behaviour, with a poorer prognosis compared to other subtypes. Recently, tumor-infiltrating lymphocytes (TILs) have been proposed as a predictive biomarker for a better clinical outcome and pathological response (pR) after neoadjuvant chemotherapy (NACT) in TNBC. These data confirm the role of the immune system in the neoplastic progression and in the response to therapy. We performed a retrospective analysis of 54 pre-NACT biopsies of TNBC and compared both the percentage of stromal TILs and the degree of PD-L1 expression with the extent of pR to standard NACT. A pathological complete response (pCR) was achieved in 35% of cases. Univariate analysis showed (i) a significant association between PD-L1 expression in ≥25% of neoplastic cells and the achievement of a pCR (p=0.024); (ii) a significantly higher frequency of pCR in cases showing ≥50% stromal TILs (p<0.001). However in the multivariate analysis only PD-L1 expression on tumor cells remained significantly associated with pCR (OR = 1,13; 95% CI 1,01–1,27), suggesting that the expression of this biomarker could be associated with a subpopulation of TNBC more likely to respond to chemotherapy. These data need to be confirmed by larger studies.

Sign in / Sign up

Export Citation Format

Share Document